Find Clinical Trials in Arkansas for Hepatitis

All Categories ... Most Often Searched» ... Hepatitis» ... Arkansas

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668; Drug: BI 207127 Dose 1; Drug: BI 207127 Dose 2; Drug: Faldaprevir; Drug: Ribavirin; Drug: BI 207127 Placebo
Sponsors: Presidio Pharmaceuticals, Inc.; Presidio Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 201335; Drug: ribavirin; Drug: BI 207127; Drug: Telaprevir; Drug: ribavirin; Drug: Pegylated Interferon
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified May 2013
Intensive Models of HCV Care for Injection Drug Users

Conditions: Hepatitis C; Medication Adherence
Intervention: Other: Intensive Models (mDOT and CGT) of HCV Care
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting - verified May 2013
A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant

Condition: Hepatitis B
Intervention: Drug: Zutectra
Sponsors: Biotest; Biotest
Recruiting - verified May 2013
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Condition: Hepatitis C
Interventions: Drug: EDP239; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavrin; Drug: Pegylated Interferon alpha 2-alpha (PegINF); Drug: Telaprevir
Sponsors: AbbVie; AbbVie
Not yet recruiting - verified April 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study to Collect Blood Biomarker Samples From Patients With Chronic Hepatitis B Who Received Treatment With Pegasys (Peginterferon Alfa-2a) +/- Nucleos(t)Ide Analogue

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013
Optimizing Kidney Transplant Informed Consent

Condition: End-stage Kidney Disease
Intervention: Behavioral: Inform Me: web-based education tool
Sponsors: Northwestern University; Northwestern University; University of Alabama at Birmingham
Not yet recruiting - verified May 2013
Insulin Resistance in HCV Infection

Conditions: Insulin Secretion; Insulin Resistance
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2013
IDX719 in Combination With Simeprevir and Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection

Condition: Chronic Hepatitis C Virus
Interventions: Drug: IDX719; Drug: IDX719 placebo; Drug: simeprevir; Drug: ribavirin
Sponsors: Idenix Pharmaceuticals; Idenix Pharmaceuticals; Janssen Research & Development, LLC
Recruiting - verified May 2013
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C

Condition: Hepatocellular Cancer
Intervention: Drug: Sorafenib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder

Condition: Hepatitis B
Intervention: Biological: Engerix™-B Kinder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2013
Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)

Condition: Hepatitis C
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified May 2013
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Conditions: Hepatitis C, Chronic; Infection
Interventions: Drug: TMC435; Drug: Pegylated interferon alfa-2a (PegIFNα-2a); Drug: Ribavirin (RBV)
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Not yet recruiting - verified May 2013
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Conditions: Hepatic Failure; Hepatic Impairment; Chronic Hepatitis C Infection With Hepatic Coma
Interventions: Drug: 2.0mg Buprenorphine/0.5mg Naloxone; Drug: Promethazine
Sponsors: Reckitt Benckiser Pharmaceuticals Inc.; Reckitt Benckiser Pharmaceuticals Inc.
Recruiting - verified May 2013
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Conditions: Chronic Hepatitis C; CHC; HCV; Hepatitis C
Interventions: Drug: VX-135; Drug: Daclatasvir
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified April 2013
Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

Condition: Chronic HBV With Severe Exacerbation
Interventions: Drug: Tenofovir; Drug: lamivudine
Sponsors: Kaohsiung Veterans General Hospital.; Kaohsiung Veterans General Hospital.
Recruiting - verified May 2013
Brief Intervention for Rural Women at High Risk for HIV/HCV

Conditions: Acquired Immune Deficiency Syndrome Virus; Hepatitis C; Drug Abuse
Intervention: Other: MI-based HIV Risk Reduction
Sponsors: University of Kentucky; University of Kentucky
Not yet recruiting - verified April 2013
Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)

Condition: Hepatitis A
Intervention:
Sponsors: Sanofi; Sanofi Pasteur, a Sanofi Company
Recruiting - verified April 2013
Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects

Condition: Hepatitis C Virus
Interventions: Drug: sovaprevir; Drug: ACH-3102; Drug: Ribavirin; Drug: Placebo
Sponsors: Achillion Pharmaceuticals; Achillion Pharmaceuticals
Recruiting - verified May 2013
Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation

Conditions: Hepatitis C Virus; Liver Transplantation
Intervention:
Sponsors: Schiano, Thomas D., MD; Schiano, Thomas D., MD; Merck Sharpe & Dohme Corporation; Mount Sinai School of Medicine
Not yet recruiting - verified April 2013
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Condition: Hepatitis C
Interventions: Drug: Ribavirin; Drug: HCQ
Sponsors: BioLineRx, Ltd.; BioLineRx, Ltd.
Recruiting - verified April 2013
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection.

Condition: Hepatitis C Virus
Interventions: Drug: Sofosbuvir; Drug: Ribavirin (RBV)
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
3E Extension Study

Condition: Chronic Hepatitis B
Intervention: Drug: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; Major Science and Technology Special Project of China 12th Five-year
Recruiting - verified April 2013
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Condition: Hepatitis C
Intervention: Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2013
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Conditions: Chronic Hepatitis C Infection; HCV Genotype 1b
Interventions: Drug: 1- Erlotinib; Drug: placebo
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Not yet recruiting - verified April 2013
Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Conditions: Chronic Hepatitis B; Inadequate Response; Nucleos(t)Ide Analogues Treatment
Intervention: Drug: Entecavir, Adefovir
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; Major Science and Technology Special Project of China Eleventh Five-year
Recruiting - verified April 2013
A Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Alcoholic Hepatitis Who Have Failed Steroid Therapy

Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD; Other: Standard of Care treatment
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Not yet recruiting - verified April 2013
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before.

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Telaprevir; Drug: Pegylated Interferon alpha 2-alpha (PegIFN)
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
HCV Treatment in HIV Co-Infected Patients in Asia

Conditions: Hepatitis C; HIV
Intervention: Drug: Pegylated-Interferon and Ribavirin
Sponsors: amfAR, The Foundation for AIDS Research; amfAR, The Foundation for AIDS Research; Kirby Institute
Not yet recruiting - verified April 2013
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Condition: Hepatitis C
Intervention: Drug: GSK2336805
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2013
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Condition: Hepatitis C
Interventions: Drug: BZF961; Drug: Ritonavir; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years.

Conditions: Meningococcal Vaccine; rLP2086; Hepatitis A Virus Vaccine; N Meningitidis Serogroup B; Meningitis
Interventions: Biological: rLP2086; Biological: rLP2086; Biological: rLP2086; Biological: Havrix (HAV); Biological: Saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

Conditions: Chronic Hepatitis C; Chronic Hepatitis B
Interventions: Other: Regression of fibrosis; Other: Specific risk factors related to hepatocellular carcinoma
Sponsors: University of Arkansas; University of Arkansas; University of North Carolina, Chapel Hill; University of Toronto; University of Calgary
Not yet recruiting - verified April 2013
Interaction Between Paroxetine and Telaprevir

Conditions: Hepatitis C Infection; Depression
Interventions: Drug: Paroxetine; Drug: telaprevir
Sponsors: Radboud University; Radboud University; Janssen, LP
Not yet recruiting - verified April 2013
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, or 3 HCV Infection

Condition: Chronic Hepatitis C
Interventions: Drug: SOF/LDV FDC; Drug: SOF; Drug: RBV; Drug: PEG; Drug: GS-9669
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Condition: Infection
Interventions: Drug: Pegylated Interferon Alfa 2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Conditions: Thrombocytopenia; Hepatitis C
Intervention: Drug: Eltrombopag
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; GlaxoSmithKline
Recruiting - verified March 2013
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Condition: Hepatitis C, Chronic
Interventions: Drug: Faldaprevir; Drug: BI 207127; Drug: BI 207127 high dose; Drug: Ribavirin placebo; Drug: Faldaprevir; Drug: BI 207127 high dose; Drug: BI 207127; Drug: Faldaprevir; Drug: BI 207127 high dose placebo; Drug: Ribavirin; Drug: Faldaprevir; Drug: Faldaprevir placebo; Drug: BI 207127 low dose; Drug: BI 207127 low dose placebo; Drug: Faldaprevir; Drug: BI 207127 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
UCLA-Amity Parolee Health Promotion Study

Conditions: Hepatitis B; Hepatitis C; HIV; Drug Addiction
Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach; Behavioral: Parolee Brief HBV Program + Phone Coach; Behavioral: Usual Care Group
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2013
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis

Condition: Severe Alcoholic Hepatitis
Interventions: Drug: G-CSF; Drug: Placebo
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Not yet recruiting - verified March 2013
Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study

Condition: Chronic Hepatitis B
Intervention: Biological: HBV vaccine (Engerix B)
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Not yet recruiting - verified March 2013
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Condition: Chronic Hepatitis C
Intervention: Drug: GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
New Methods to Measure the Immune Response to Hepatitis B Vaccine

Condition: Hepatitis B
Intervention: Drug: Hepatitis B vaccine
Sponsors: University of Oxford; University of Oxford
Recruiting - verified March 2013
Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B

Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Peginterferon and Tenofovir
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2013
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

Condition: Chronic Hepatitis B
Intervention: Drug: HBsAg vaccine with Entecavir
Sponsors: Genexine Co., Ltd.; Genexine Co., Ltd.
Recruiting - verified March 2013
Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.

Condition: Hepatitis B
Intervention:
Sponsors: Hopital Lariboisière; Hopital Lariboisière
Recruiting - verified March 2013
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors

Condition: Chronic Hepatitis C Virus Infection
Intervention:
Sponsors: Intermountain Health Care, Inc.; Intermountain Health Care, Inc.
Not yet recruiting - verified March 2013
Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Prednisolone in Severe Acute Alcoholic Hepatitis

Condition: Acute Alcoholic Hepatitis
Interventions: Drug: Anakinra; Drug: Pentoxifylline; Drug: Zinc Sulfate; Drug: Methylprednisolone
Sponsors: University of Texas Southwestern Medical Center; Mack Mitchell; National Institute on Alcohol Abuse and Alcoholism (NIAAA); The Cleveland Clinic; University of Massachusetts, Worcester; University of Louisville
Not yet recruiting - verified March 2013
THISTLE - The HIV-HCV Silibinin Trial

Conditions: HIV; Hepatitis C
Intervention: Drug: Intravenous Silibinin (iSIL)
Sponsors: University of Zurich; University of Zurich
Not yet recruiting - verified March 2013
Combination Therapy for Chronic Hepatitis C Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: Fixed Dose GS-7977/GS-5885; Drug: GS-7977 + GS-9669
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2012
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Conditions: Hepatitis; Viruses; Carcinoma; Hepatitis, Viral, Human; Liver Cirrhosis
Intervention: Biological: Civacir® 10%
Sponsors: Biotest Pharmaceuticals Corporation; Biotest Pharmaceuticals Corporation
Not yet recruiting - verified March 2013
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Condition: Hepatitis C
Intervention: Drug: SOF in combination with PEG and RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for Ribavirin
Sponsors: AbbVie; AbbVie
Recruiting - verified April 2013
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Condition: Hepatitis C Infection
Interventions: Drug: SB9200; Drug: SB9200; Drug: Placebo
Sponsors: INC Research; INC Research; Spring Bank Pharmaceuticals, Inc
Recruiting - verified April 2013
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Condition: Hepatitis C
Interventions: Drug: Peginterferon alfa 2a; Drug: Ribavirin; Drug: Placebo matching Daclatasvir; Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2013
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Condition: Hepatitis C
Interventions: Biological: Pegylated Interferon Lambda; Drug: Ribasphere; Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2013
HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B

Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013
HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Condition: HIV
Intervention: Drug: FTC/TDF
Sponsors: HIV Prevention Trials Network; HIV Prevention Trials Network
Not yet recruiting - verified March 2013
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests

Conditions: HIV; Hepatitis B; Hepatitis C; Carcinoma, Hepatocellular; AIDS
Interventions: Other: ELISA; Other: Rapid Test
Sponsors: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba; Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); Gilead Sciences; Roche Pharma AG; Mairie de Paris; Biomerieux
Recruiting - verified May 2013
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Conditions: Chronic Hepatitis C; Human Immunodeficiency Virus
Interventions: Drug: sofosbuvir + Ribavirin (RBV); Drug: sofosbuvir + Ribavirin (RBV)
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Condition: Hepatitis B Vaccine
Interventions: Biological: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.; Biological: EngerixTM-B
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Public Private Partnership with Institute for Medical Immunology (Universite Libre de Bruxelles); Region Wallonne
Recruiting - verified March 2013
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Condition: Post-transplant Recurrent Hepatitis C
Intervention: Drug: Sofosbuvir + RIbavirin +/- Pegylated Interferon
Sponsors: Gilead Sciences; Gilead Sciences
Available - verified January 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adult Liver Transplant Recipients

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: ribavirin (RBV)
Sponsors: AbbVie; AbbVie
Recruiting - verified February 2013
Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-naïve Patients With Chronic Hepatitis B in Korea

Condition: Chronic Hepatitis B
Intervention:
Sponsors: Gachon University Gil Medical Center; Gachon University Gil Medical Center
Not yet recruiting - verified January 2013
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

Condition: Hepatitis C Infection
Intervention:
Sponsors: Southern Illinois University; Southern Illinois University
Recruiting - verified January 2013
HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Condition: Chronic Hepatitis B
Interventions: Drug: PEG-interferon-Alfa-2A; Drug: Nucleosides
Sponsors: Pusan National University Hospital; Pusan National University Hospital
Not yet recruiting - verified January 2013
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Condition: Hepatitis C
Interventions: Drug: boceprevir; Biological: PegIFN-2b; Drug: RBV
Sponsors: Merck; Merck
Not yet recruiting - verified April 2013
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

Condition: Hepatitis B
Interventions: Drug: Entecavir prophylaxis; Drug: Therapeutic entecavir
Sponsors: Peking University; Peking University
Recruiting - verified January 2013
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy

Condition: Hepatitis B
Intervention: Drug: Entecavir prophylaxis
Sponsors: Peking University; Peking University
Recruiting - verified January 2013
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers

Condition: Viral Hepatitis C
Intervention: Drug: Telaprevir
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2013
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease

Condition: Fatty Liver
Interventions: Other: High fat meal; Drug: Morphine
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of North Carolina, Greensboro
Recruiting - verified January 2013
Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan

Conditions: Uremia; Viral Hepatitis
Intervention: Other: blood sampling
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting - verified December 2012
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Conditions: Chronic Hepatitis B; HBeAg Positive; HBsAg Positive; HBV DNA Above 2000IU/ML
Interventions: Drug: Ypeginterferon alfa-2b; Drug: Pegasys
Sponsors: Xiamen Amoytop Biotech Co., Ltd.; Xiamen Amoytop Biotech Co., Ltd.; Peking University First Hospital
Recruiting - verified December 2012
Liver Transplantation in Alcoholic Hepatitis

Condition: Alcoholic Hepatitis
Intervention:
Sponsors: Sociedad Española de Trasplante Hepático; Sociedad Española de Trasplante Hepático; Fundación Mutua Madrileña
Not yet recruiting - verified January 2013
Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Cairo University; Cairo University
Recruiting - verified April 2013
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment

Conditions: Alcoholic Hepatitis; Alcoholic Cirrhosis
Intervention: Procedure: Liver transplantation
Sponsors: University Hospital, Lille; University Hospital, Lille; Ministry of Health, France
Recruiting - verified December 2012
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Condition: Hepatitis C
Interventions: Drug: boceprevir; Biological: PegIFN-2b; Drug: RBV
Sponsors: Merck; Merck
Recruiting - verified March 2013
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Peginterferon Lambda-1a; Drug: Ribavirin; Biological: Peginterferon alfa-2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2013
Eltrombopag Phase III Study In Chinese Chronic ITP Patients

Condition: Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Condition: Chronic Hepatitis C(CHC)
Interventions: Drug: MP-424; Drug: RBV; Drug: IFN beta
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Toray Industries, Inc
Recruiting - verified December 2012
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Condition: Chronic Hepatitis C (CHC)
Interventions: Drug: MP-424; Drug: RBV; Drug: PEG-IFN alfa-2a
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified December 2012
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir + ritonavir; Drug: danoprevir + ritonavir; Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

Condition: Hiv
Intervention: Drug: Regimen:TDF+3TC+EFV
Sponsors: National Center for AIDS/STD Control and Prevention, China CDC; National Center for AIDS/STD Control and Prevention, China CDC; Gilead Sciences
Recruiting - verified December 2010
Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand

Conditions: Hepatitis B Chronic Infection; Pregnancy
Interventions: Drug: tenofovir disoproxil fumarate; Drug: placebo
Sponsors: Institut de Recherche pour le Developpement; Institut de Recherche pour le Developpement; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Centers for Disease Control and Prevention; Gilead Sciences
Recruiting - verified January 2013
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Mild or Moderate Hemophilia

Condition: Hepatitis C Virus
Interventions: Biological: Pegylated-Interferon-lambda; Drug: Ribavirin; Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified January 2013
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

Condition: Early Chronic Hepatitis C
Intervention: Drug: TPV/PEG-IFN/RBV
Sponsors: Kirby Institute; Kirby Institute; Janssen-Cilag Ltd.
Not yet recruiting - verified December 2012
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients

Conditions: Hepatitis C (HCV); Acupuncture
Intervention: Device: Acupuncture
Sponsors: Ziv Hospital; Assy Nimer
Not yet recruiting - verified December 2012
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection

Condition: Chronic Hepatitis C Virus
Intervention: Drug: GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified November 2012
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Conditions: Healthy; Hepatitis C
Interventions: Drug: BMS-986094/INX-08189; Drug: Placebo matching BMS-986094/INX-08189
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2013
TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

Condition: Chronic Hepatitis B
Interventions: Drug: Lamivudine plus adefovir; Drug: Tenofovir
Sponsors: Keimyung University Dongsan Medical Center; Keimyung University Dongsan Medical Center; Kyungpook National University; Daegu Catholic University Medical Center; DongGuk University; Pusan National University Hospital; Yeungnam University
Recruiting - verified November 2012
A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study

Condition: Hepatitis C
Interventions: Drug: ABT-450/ritonavir; Drug: ABT-333; Drug: ABT-267
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Not yet recruiting - verified January 2013
To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B

Condition: Spontaneous Reactivation of Hepatitis B
Interventions: Drug: Tenofovir + Telbivudine; Drug: Tenofovir
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Not yet recruiting - verified November 2012
Study for Consolidation Period of Chronic Hepatitis B

Condition: HBeAg Seroconversion
Intervention:
Sponsors: Tainan Municipal Hospital; Tainan Municipal Hospital
Not yet recruiting - verified November 2012
"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection

Condition: Hepatitis B
Intervention:
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified November 2012
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Conditions: Chronic Hepatitis C; End Stage Renal Disease
Interventions: Drug: Ribavirin; Drug: Peginterferon; Drug: Boceprevir
Sponsors: Liver Institute of Virginia; Liver Institute of Virginia; Merck; Chronic Liver Disease Foundation
Not yet recruiting - verified November 2012
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Condition: Hepatitis C
Intervention: Drug: Miravirsen sodium
Sponsors: Santaris Pharma A/S; Santaris Pharma A/S
Recruiting - verified November 2012
A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Condition: Hepatitis B
Interventions: Drug: Tenofovir; Biological: Pegylated interferon alpha-2b
Sponsors: Merck; Merck
Not yet recruiting - verified March 2013
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435; Drug: Peginterferon-alpha (PegIFNα-2a); Drug: Ribavirin (RBV); Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2013
In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Condition: Hepatitis C
Interventions: Drug: Pegylated interferon alpha; Drug: Ribavirin
Sponsors: Fremantle Hospital and Health Service; Fremantle Hospital and Health Service
Recruiting - verified March 2013
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Conditions: Cervical Intraepithelial Neoplasia; Cervical Cancer; Vaginal Intraepithelial Neoplasia; Vulvar Intraepithelial Neoplasia; Persistent Infection
Interventions: Biological: HPV Vaccine; Biological: HEV vaccine
Sponsors: Xiamen University; Xiamen University; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co.; Ministry of Science and Technology of the People´s Republic of China
Recruiting - verified November 2012
Training Study to Characterise Biomarkers to the Engerix B Vaccine

Condition: Healthy
Interventions: Biological: Engerix B Vaccine; Biological: Placebo
Sponsors: University of Surrey; University of Surrey; Innovative Medicines Initiative.; GlaxoSmithKline
Recruiting - verified February 2013
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: VX-135; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China

Condition: Chronic Hepatitis B
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2013
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

Condition: Hepatitis C
Intervention:
Sponsors: Idenix Pharmaceuticals; Idenix Pharmaceuticals
Recruiting - verified November 2012
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

Conditions: Liver Cirrhosis; Hepatitis B
Interventions: Drug: Entecavir; Drug: Lamivudine plus Adefovir Dipivoxil
Sponsors: Beijing Friendship Hospital; Beijing Friendship Hospital; Peking University First Hospital; Peking University People's Hospital; Beijing YouAn Hospital; Beijing Tiantan Hospital; Beijing Ditan Hospital; Peking Union Medical College Hospital; Beijing 302 Hospital
Recruiting - verified October 2012
Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Liver Failure

Condition: Liver Failure
Interventions: Other: Conventional plus UC-MSC treatment; Other: Conventional plus PE treatment; Other: Conventional plus UC-MSC and PE therapy; Other: Conventional treatment
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified February 2013
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Condition: Hepatitis C
Interventions: Biological: Peginterferon Lambda-1a; Biological: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Daclatasvir; Drug: Telaprevir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2013
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

Condition: Hepatitis C
Interventions: Drug: MK-5172; Drug: MK-8742; Drug: Placebo; Drug: Ribavirin
Sponsors: Merck; Merck
Recruiting - verified April 2013
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: ribavirin (RBV)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013
Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy

Condition: C Hepatitis, Tri Therapy
Intervention: Biological: Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble
Recruiting - verified January 2013
A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

Condition: HCV and HIV Seropositive Coinfection
Interventions: Drug: boceprevir; Drug: Ribavirin; Drug: Peginterferon alfa-2a; Drug: Peginterferon alfa-2b
Sponsors: Fundacion Clinic per a la Recerca Biomédica; Anna Cruceta
Not yet recruiting - verified October 2012
Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

Condition: Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate; Drug: Entecavir
Sponsors: New Discovery LLC; New Discovery LLC
Not yet recruiting - verified October 2012
Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study

Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir; Drug: entecavir
Sponsors: Korea University; Korea University; Gilead Sciences
Not yet recruiting - verified March 2013
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

Condition: Hepatitis C Recurrence After Liver Transplant
Interventions: Drug: EVL arm; Drug: MMF arm
Sponsors: Hospital Vall d'Hebron; Hospital Vall d'Hebron
Recruiting - verified October 2012
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

Condition: Chronic Hepatitis C Infection
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified October 2012
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression

Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: nucleos(t)ide analogues
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified March 2013
A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2012
Viral Kinetics in HCV Clearance in Subjects With Hemophilia

Condition: Hepatitis C With Hemophilia
Interventions: Other: Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks); Other: No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)
Sponsors: University of Cincinnati; Kenneth Sherman; National Heart, Lung, and Blood Institute (NHLBI); Vertex Pharmaceuticals Incorporated; Genentech
Recruiting - verified January 2013
Comparison of 2 IUDnCT Devices

Condition: Comparing Safety With Regard to HIV Disease Progression and Acceptability of Levonorgestrel IUD to the Copper IUD Among HIV-infected ART-naïve Women.
Intervention: Device: Mirena levonorgestrel IUD and copper T-380a IUD
Sponsors: FHI 360; FHI 360; University of Cape Town; The City University of New York
Not yet recruiting - verified November 2012
Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C

Conditions: Hepatitis C; Alcohol Abuse
Interventions: Other: Web-Based Brief Alcohol Intervention; Other: Usual Care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253

Condition: Hepatitis B, Chronic
Intervention: Other: Interleukin 28B testing
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus

Conditions: Acute on Chronic Hepatic Failure; Liver Failure; Hepatitis E Infection
Interventions: Drug: Ribavirin; Drug: Placebo
Sponsors: All India Institute of Medical Sciences, New Delhi; All India Institute of Medical Sciences, New Delhi
Recruiting - verified September 2012
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected Patients

Condition: Chronic Hepatitis C
Interventions: Drug: TMC647055; Drug: TMC435; Drug: Ritonavir; Drug: Ribavirin; Drug: Pegylated interferon alpha-2a (PegIFN)
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα

Conditions: Chronic Hepatitis B; Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis; Juvenile Idiopathic Arthritis
Interventions: Drug: Entecavir; Drug: Placebo
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Konkuk University Medical Center; Kyungpook National University; Kyunghee University Medical Center; Kyung Hee University Gangdong Hospital; Gachon University Gil Medical Center; Daegu Catholic University Medical Center; Eulji University Hospital; SMG-SNU Boramae Medical Center; The Catholic University of Korea; Severance Hospital; Ajou University School of Medicine; Ewha Womans University; Inha University Hospital; Chonnam National University Hospital; Chonbuk National University Hospital; Chungnam National University Hospital; Hallym University Medical Center; Hanyang University; Dong-A University; Korea University Guro Hospital
Recruiting - verified April 2013
SIMpill Medication Dispensing Device in the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Intervention: Device: SIMpill device
Sponsors: University of Chicago; University of Chicago
Not yet recruiting - verified September 2012
Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis

Conditions: Hypoxic Hepatitis; Ischemic Hepatitis; Shock Liver; Hypoxic Liver Injury; Acute Liver Failure
Intervention: Device: MARS
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified September 2012
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Condition: Chronic Hepatitis C Virus
Intervention: Drug: Pegylated interferon alpha-2a
Sponsors: King Abdulaziz Medical City; King Abdulaziz Medical City
Recruiting - verified September 2012
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: Ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Conditions: Hepatitis C; Cirrhosis; Portal Hypertension; With or Without Liver Decompensation
Interventions: Drug: GS-7977; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

Conditions: Liver Fibrosis; Hepatitis C; HIV; HIV/HCV Co-infection
Intervention: Biological: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2012
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)

Conditions: Hepatitis C, Chronic; Liver Diseases; Interferon Deficiency
Intervention: Drug: interferon alpha 2b
Sponsors: First Hospital of Jilin University; Junqi Niu; Chinese Academy of Sciences
Recruiting - verified January 2013
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B

Condition: Chronic Hepatitis B
Intervention:
Sponsors: Peking University First Hospital; Peking University First Hospital; Beijing Municipal Science & Technology Commission
Recruiting - verified September 2012
A Study to Evaluate Fine Needle Aspiration as a Method for MK-7009 Liver Pharmacokinetic Measurement in Participants With Chronic Hepatitis C (MK-7009-048)

Condition: Chronic Hepatitis C
Interventions: Drug: MK-7009; Biological: Peg-IFN alfa-2b; Biological: Ribavirin; Procedure: Liver samples from FNA and CNB
Sponsors: Merck; Merck
Recruiting - verified November 2012
Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients

Condition: Hepatitis C
Intervention: Biological: Ad6NSmut, MVA-NSmut
Sponsors: Okairos; Okairos; EU
Recruiting - verified October 2012
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Intervention: Other: Interleukin 28B testing
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

Conditions: Chronic Hepatitis c; Insulin Resistance
Interventions: Drug: metformin; Drug: pegylated-IFN; Drug: ribavirin
Sponsors: Kaohsiung Veterans General Hospital.; Kaohsiung Veterans General Hospital.
Recruiting - verified August 2012
Low Grade Lymphoma

Condition: Indolent Lymphoproliferative Disorders
Intervention: Biological: Vaccin GenHevac B Pasteur
Sponsors: Central Hospital, Nancy, France; Central Hospital, Nancy, France
Recruiting - verified July 2012
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis

Condition: Autoimmune Hepatitis
Interventions: Other: conventional plus UC-MSC treatment; Other: Conventional plus placebo treatment
Sponsors: Beijing 302 Hospital; Beijing 302 Hospital
Recruiting - verified August 2012
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

Conditions: HIV; Hepatitis C
Intervention: Drug: Rifaximin
Sponsors: Mount Sinai School of Medicine; Douglas T. Dieterich; Salix Pharmaceuticals
Recruiting - verified October 2012
An Observational Study of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

Condition: Genotype 4 Chronic Hepatitis C Infection
Interventions: Drug: Boceprevir; Drug: Peginterferon alfa-2b; Drug: ribavirin
Sponsors: Theodor Bilharz Research Institute; Theodor Bilharz Research Institute
Not yet recruiting - verified July 2012
Multiple Ascending Dose

Condition: Hepatocellular Carcinoma
Interventions: Biological: BMS-936558 (Anti-PD-1 antibody); Biological: BMS-936558 (Anti-PD-1 antibody)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection

Condition: Chronic Hepatitis B Infection
Interventions: Drug: Tenofovir DF; Drug: Tenofovir DF Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified February 2013
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo; Drug: JNJ-47910382
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Intervention: Drug: Reiferon retard
Sponsors: MinaPharm Pharmaceuticals; MinaPharm Pharmaceuticals
Recruiting - verified January 2013
Prevalence of Hepatitis B Infection in the Galilee Region, Israel

Condition: Hepatitis B
Intervention:
Sponsors: Western Galilee Hospital-Nahariya; Western Galilee Hospital-Nahariya
Not yet recruiting - verified July 2012
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients

Conditions: Opioid Dependence; Hepatitis; HIV
Intervention: Other: computerized Cognitive Behavioral Therapy (CBT)
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2012
Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis

Conditions: Autoimmune Hepatitis; Cirrhosis
Intervention: Dietary Supplement: High protein high fiber diet
Sponsors: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting - verified July 2012
Dose Ranging of GSK2336805 in Combination Therapy

Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805 40 mg; Drug: GSK2336805 60 mg; Drug: Pegylated interferon alpha-2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified January 2013
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms

Condition: Chronic Hepatitis C
Intervention:
Sponsors: Foundation for Liver Research; Foundation for Liver Research; Janssen-Cilag B.V.
Recruiting - verified January 2013
A Study of the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Participants With Chronic Hepatitis B (P08450 AM1)

Condition: Hepatitis B, Chronic
Interventions: Biological: PEG-Intron™; Biological: PEGASYS™
Sponsors: Merck; Merck
Recruiting - verified March 2013
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Condition: Chronic Hepatitis C
Interventions: Drug: Boceprevir; Drug: Peginterferon Alfa-2b 1.5 mcg/kg/week; Drug: Ribavirin
Sponsors: Merck; Merck
Not yet recruiting - verified November 2012
Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B

Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Tenofovir; Drug: Tenofovir; Drug: Entecavir
Sponsors: Asan Medical Center; Asan Medical Center; Samsung Medical Center; Konkuk University Medical Center; Korea University Guro Hospital; Seoul National University Hospital
Recruiting - verified September 2012
Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B

Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Tenofovir; Drug: Entecavir; Drug: Tenofovir
Sponsors: Asan Medical Center; Asan Medical Center; Samsung Medical Center; Konkuk University Medical Center; Korea University Guro Hospital; Seoul National University Hospital
Recruiting - verified September 2012
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Condition: Hepatitis C, Chronic
Intervention: Drug: SB-497115-GR
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Histologic Changes and Noninvasive Assessments in HCV Patients With Peginterferon Alpha-2a Plus Ribavirin Therapy

Condition: Chronic Hepatitis C
Intervention: Device: chronic hepatitis C
Sponsors: Seoul National University Boramae Hospital; Seoul National University Boramae Hospital; Roche Pharma AG
Recruiting - verified April 2013
Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

Condition: Hepatic Neoplasm Malignant Recurrent
Interventions: Drug: NIK-333(peretinoin); Drug: Placebo
Sponsors: Kowa Company, Ltd.; Kowa Company, Ltd.
Recruiting - verified September 2012
ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

Condition: Sequela of Chronic Liver Disease
Intervention:
Sponsors: Turkiye Yuksek Ihtisas Education and Research Hospital; Turkiye Yuksek Ihtisas Education and Research Hospital
Recruiting - verified July 2012
Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Intervention: Drug: Peginterferon alfa-2a plus Ribavirin
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Not yet recruiting - verified June 2012
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5466731; Drug: RO5190591; Drug: ritonavir; Drug: ribavirin [Copegus]; Drug: RO5024048
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Comparison Between Lamivudine and Entecavir Treatment in Patients

Condition: Chronic Hepatitis B
Interventions: Drug: Lamivudine; Drug: Entecavir
Sponsors: Taichung Veterans General Hospital; Taichung Veterans General Hospital; GlaxoSmithKline
Recruiting - verified February 2013
BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: BIP 48 (Peginterferon alfa 2b 48kDA); Drug: Peginterferon alfa 2a 40kDA; Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
Sponsors: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz); The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz); Hospital de Clinicas de Porto Alegre
Recruiting - verified November 2011
Efficacy of Short-term Immunosuppressive Therapy and Anti-allergenic Therapy in Severe Acute Exacerbation of Chronic Hepatitis B

Condition: Severe Acute Exacerbation of Chronic Hepatitis B
Intervention: Drug: methylprednisolone
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified January 2013
Genetic Studies of Non-Alcoholic Fatty Liver Disease

Conditions: Fatty Liver; Liver Cirrhosis; Non-Alcoholic Fatty Liver Disease; Liver Transplantation; Genetics
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2013
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon alfa-2a (pegIFNα-2a); Drug: Ribavirin; Drug: Ribavirin; Drug: Daclatasvir; Drug: Placebo matching Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2013
Open-Label Study of GS-7977+ Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Condition: Chronic Hepatitis C
Interventions: Drug: GS-7977 in combination with ribavirin; Drug: GS-7977 400mg QD+ RBV BID+ PEG
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
HBV DNA Levels During Pregnancy in Chronic Hepatitis B

Conditions: Hepatitis B; Pregnancy
Intervention:
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified May 2012
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059 AM1)

Condition: Hepatitis C, Chronic
Interventions: Drug: PEG-IFN alfa-2b; Drug: ribivirin
Sponsors: Merck; Merck
Recruiting - verified April 2013
Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection

Condition: Hepatitis B
Interventions: Biological: GC1102; Other: JW normal saline
Sponsors: Green Cross Corporation; Green Cross Corporation
Recruiting - verified August 2012
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Clalit Health Services
Recruiting - verified May 2013
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Condition: Hepatitis C Virus
Interventions: Biological: Peginterferon Lambda-1a; Biological: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2013
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Telbivudine; Drug: Entecavir
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified June 2012
Antiviral Efficacy of Switching to ETV Plus TDF

Condition: Chronic Hepatitis B
Interventions: Drug: Group A (Zeffix, Sebivo, Hepsera); Drug: Group B (Baraclude, Viread)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital; Soonchunhyang University Hospital; Pusan National University Hospital; Kyungpook National University; Hallym University Medical Center; Chonbuk National University Hospital
Not yet recruiting - verified July 2012
Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection

Condition: Chronic Hepatitis B
Intervention: Drug: Entecavir + Tenofovir (MDR group)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital
Not yet recruiting - verified July 2012
Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment

Conditions: Hepatitis; Tuberculosis; hepatitisB
Intervention: Drug: entecavir (BARACLUDE®)
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Not yet recruiting - verified November 2012
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Interventions: Drug: boceprevir; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034 AM4)

Condition: Chronic Hepatitis C
Interventions: Drug: Boceprevir; Drug: Peginterferon alpha-2b; Drug: Ribavirin; Drug: Boceprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Merck; Merck
Recruiting - verified April 2013
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

Conditions: Hepatitis B; HBV
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620; Drug: Multiple Ascending Dose (MAD) Cohorts
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Condition: Hepatitis B
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620; Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)

Condition: Chronic Liver Disease
Intervention: Drug: Perfusion MRI
Sponsors: Mount Sinai School of Medicine; Bachir Taouli
Recruiting - verified February 2013
Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Condition: Hepatitis C
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: telaprevir
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2012
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Conditions: Hepatitis C Virus; Liver Transplant Recipient; Recurrent Fibrosis
Interventions: Drug: Rifaximin; Drug: Placebo
Sponsors: Columbia University; Columbia University
Recruiting - verified August 2012
The Health Access and Recovery Peer Program

Conditions: Hypertension; Arthritis; Coronary Artery Disease; Hepatitis; Diabetes; Asthma; Hyperlipidemia; HIV
Intervention: Behavioral: HARP Intervention
Sponsors: National Institute of Mental Health (NIMH); Emory University
Recruiting - verified March 2013
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg; Drug: JNJ-47910382 90 mg; Drug: JNJ-47910382 300 mg; Drug: JNJ-47910382 400 or 450 mg; Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2013
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2012
A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection

Condition: Hepatitis C
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Recruiting - verified May 2012
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV); Drug: Daclatasvir (DCV); Drug: PBO matching ASV; Drug: Placebo (PBO) matching DCV; Drug: Pegylated-interferon alfa 2a (PegIFN); Drug: Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2012
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment

Condition: Hepatitis C
Intervention: Drug: Boceprevir
Sponsors: University of Calgary; University of Calgary; Merck
Recruiting - verified May 2013
Herpes Simplex Type 1 Suppression in Hepatitis C

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified March 2013
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir; Drug: Daclatasvir; Drug: Peg-interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified September 2012
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection

Condition: Hepatitis C Virus Infection, Response to Therapy of
Intervention: Behavioral: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Health Research Institutes, Taiwan
Recruiting - verified November 2012
Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function

Condition: Vitamin A Deficiency
Interventions: Dietary Supplement: retinyl palmitate; Dietary Supplement: Placebo
Sponsors: USDA, Western Human Nutrition Research Center; USDA, Western Human Nutrition Research Center; International Centre for Diarrhoeal Disease Research, Bangladesh; World Health Organization
Recruiting - verified November 2012
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Condition: Hepatitis C
Intervention: Drug: Sitagliptin
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified March 2013
Improving Blood Safety and HIV Testing in Brazil

Conditions: HIV; Herpes Simplex 2; Hepatitis C; Hepatitis B; Chagas Disease
Interventions: Behavioral: HIV Counseling and Testing; Behavioral: Blood Donation
Sponsors: Blood Systems Research Institute; Blood Systems Research Institute
Recruiting - verified April 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Multiple Dose Study of MK-5172 in Hepatitis C-Infected Participants (MK-5172-010 AM1)

Condition: Hepatitis
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Not yet recruiting - verified May 2013
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

Condition: Hepatitis C Infection
Intervention: Drug: ITX 5061
Sponsors: Schiano, Thomas D., MD; Schiano, Thomas D., MD; iTherX Pharma, Inc.
Recruiting - verified April 2013
Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B

Condition: Chronic Hepatitis B
Intervention: Drug: peginterferon alpha-2b
Sponsors: Foundation for Liver Research; Foundation for Liver Research
Recruiting - verified January 2013
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Telaprevir in Patients Undergoing Liver Transplantation for Hepatitis C

Condition: Hepatitis C Infection
Interventions: Biological: MBL-HCV1; Drug: Telaprevir
Sponsors: MassBiologics; MassBiologics
Recruiting - verified May 2013
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

Conditions: Hepatitis C, Chronic; Non-Alcoholic Fatty Liver Disease
Intervention: Device: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Sponsors: HepQuant, LLC; HepQuant, LLC
Recruiting - verified January 2013
Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease

Condition: Inflammatory Bowel Disease
Interventions: Biological: ENGERIX-B (HBV Vaccine); Biological: Sci-B-Vac
Sponsors: Soroka University Medical Center; Soroka University Medical Center
Recruiting - verified June 2012
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518 AM2)

Condition: Hepatitis C Chronic
Intervention:
Sponsors: Merck; Merck
Recruiting - verified May 2013
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: midazolam; Drug: BI 201335; Drug: caffeine; Drug: tolbutamide; Drug: tolbutamide; Drug: midazolam; Drug: caffeine; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: BI 201335; Drug: BI 207127; Drug: ribavirin; Drug: pegylated interferon; Drug: caffeine; Drug: tolbutamide; Drug: BI 207127; Drug: ribavirin; Drug: midazolam; Drug: BI 201335; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen

Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz; Roche Pharma AG
Recruiting - verified March 2013
36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8

Condition: Hepatitis C Infection
Intervention: Drug: Pegintron + Riba
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Merck
Recruiting - verified September 2012
3 Grams Daily Valacyclovir in Chronic Hepatitis C Infection (Phase II)

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified March 2013
Tenofovir in Chronic Hepatitis B With Mild ALT Elevation

Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir disoproxil fumarate 300mg per day; Drug: Placebo
Sponsors: E-DA Hospital; E-DA Hospital; Gilead Sciences; Taipei Institute of Pathology, Taiwan
Recruiting - verified October 2012
Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

Condition: Hepatitis C
Intervention:
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Recruiting - verified May 2013
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Condition: Hepatitis C
Intervention: Drug: Peginterferon Lambda-1a (BMS-914143)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified September 2012
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Condition: Hepatitis C
Interventions: Drug: Telaprevir + peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Available - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study

Condition: Chronic Hepatitis B
Interventions: Drug: telbivudine plus adefovir; Drug: lamivudine plus adefovir
Sponsors: Korea University; Korea University
Recruiting - verified March 2013
Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus

Conditions: Hepatitis B; Renal Failure With Tubular Necrosis
Intervention: Biological: plasma and urine samples, sample with ADN
Sponsors: University Hospital, Limoges; University Hospital, Limoges
Recruiting - verified December 2011
Telaprevir Open-Label Study in Co-Infected Patients

Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir; Drug: Telaprevir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified May 2013
Lonafarnib for Chronic Hepatitis D

Condition: Hepatitis D
Intervention: Drug: Lonafarnib
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2012
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

Condition: Chronic Hepatitis C Virus (HCV) Infection
Interventions: Drug: Telaprevir; Drug: Pegylated interferon alfa-2a; Drug: Ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified May 2013
Evaluation of Innovative Ultrasonic Techniques for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Viral Hepatitis B or C

Condition: Liver Fibrosis
Intervention: Device: Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble; Clinical investigation center, Technological innovation
Recruiting - verified February 2013
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Conditions: Hepatitis B Infection; Chronic Infection; Viremia
Intervention: Drug: TDF treatment
Sponsors: New Discovery LLC; New Discovery LLC; Gilead Sciences
Recruiting - verified March 2012
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Effects of Vitamin D on Inflammation in Liver Disease

Conditions: Hepatitis C Infection; Vitamin D Deficiency
Interventions: Drug: Vitamin D; Drug: Placebo
Sponsors: Veterans Medical Research Foundation; Veterans Medical Research Foundation
Recruiting - verified December 2012
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

Condition: Hepatitis C
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Florida
Recruiting - verified December 2012
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD treatment; Other: Standard of care (Control)
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Recruiting - verified April 2013
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified January 2013
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

Condition: Hepatitis C Infection
Intervention: Drug: Boceprevir
Sponsors: Arrowhead Regional Medical Center; Arrowhead Regional Medical Center; Southern California Transplantation Institute Research Foundation
Recruiting - verified July 2012
Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients

Conditions: Renal Allograft; Hepatitis C
Interventions: Drug: Everolimus; Drug: Cyclosporine; Drug: Tacrolimus
Sponsors: Irmandade Santa Casa de Misericórdia de Porto Alegre; Irmandade Santa Casa de Misericórdia de Porto Alegre; Novartis
Recruiting - verified March 2013
Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C

Condition: Depression
Interventions: Drug: Mirtazapine; Other: Supportive psychotherapy
Sponsors: Seoul National University Boramae Hospital; Seoul National University Boramae Hospital
Recruiting - verified April 2013
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients

Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine plus adefovir
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan
Recruiting - verified December 2011
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-650032; Drug: BMS-790052; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2012
HBsAg Related Response Guided Therapy

Condition: Hepatitis B, Chronic
Interventions: Drug: Peginterferon alfa-2a; Drug: Entecavir
Sponsors: Gangnam Severance Hospital; Gangnam Severance Hospital; Roche Pharma AG
Recruiting - verified October 2012
Pharmacogenomic Research in Korean Patients With Hepatitis C

Condition: Chronic Hepatitis C
Intervention:
Sponsors: Inje University; Inje University
Recruiting - verified September 2012
Armodafinil for Patients Starting Hepatitis C Virus Treatment

Condition: Hepatitis C
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Research Foundation for Mental Hygiene; Research Foundation for Mental Hygiene; Mount Sinai School of Medicine; Weill Medical College of Cornell University
Recruiting - verified March 2013
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)

Conditions: Chronic Hepatitis C; Menopause
Intervention: Drug: Pegylated Interferon, Ribavirin, Boceprevir
Sponsors: University of Modena and Reggio Emilia; University of Modena and Reggio Emilia; Merck
Recruiting - verified September 2012
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified March 2013
Adult-to-Adult Living Donor Transplant Cohort Study

Conditions: Liver Diseases; Hepatocellular Cancer; End Stage Liver Disease; Hepatitis C; Liver Cirrhosis
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Monique Lowe; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2012
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients

Condition: Healthy
Interventions: Drug: TG-2349; Drug: placebo
Sponsors: TaiGen Biotechnology Co., Ltd.; TaiGen Biotechnology Co., Ltd.
Recruiting - verified January 2012
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Conditions: Hepatitis; HIV/AIDS
Interventions: Drug: Boceprevir; Drug: Peg-Interferon-alfa 2B; Drug: Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2012
Safety,Effectiveness and Acceptability of Sino-implant II

Condition: Contraception
Intervention: Drug: Sino-implant (II)
Sponsors: FHI 360; FHI 360; Bill and Melinda Gates Foundation
Recruiting - verified March 2013
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

Condition: Renal Insufficiency
Intervention: Drug: ATeGe-Fresenius
Sponsors: Hospital Vall d'Hebron; Hospital Vall d'Hebron; Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified April 2013
EFFORT Extension Study

Condition: Hepatitis B, Chronic
Interventions: Drug: telbivudine (ROADMAP); Drug: Telbivudine (Standard of Care)
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; Major Science and Technology Special Project of China Eleventh Five-year; Novartis
Recruiting - verified April 2013
Staged Phase I/II Hepatitis C Prophylactic Vaccine

Condition: Hepatitis C
Interventions: Other: Placebo; Biological: MVA-NSmut; Biological: AdCh3NSmut1
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

Condition: Chronic Hepatitis C
Interventions: Drug: 48-weeks course; Drug: Ribavirin; Drug: Peginterferon alfa2a; Drug: Ribavirin
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified February 2013
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients

Condition: Hepatitis C
Intervention: Biological: implantation
Sponsors: Medgenics Medical Israel Ltd.; Medgenics Medical Israel Ltd.
Not yet recruiting - verified May 2011
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials

Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir; Drug: Asunaprevir; Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2012
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (SCH503034-P07614 AM6)

Condition: Hepatitis C, Chronic
Intervention: Drug: Boceprevir
Sponsors: Merck; Merck
Recruiting - verified April 2013
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

Conditions: HIV Infection; Hepatitis C
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2013
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients

Conditions: Chronic Hepatitis; Chronic Hepatitis C; Chronic Alcoholic Hepatitis
Intervention: Drug: High dose vitamin C
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified April 2013
Hepatitis C Rimantadine and Antiviral Combination Therapy

Condition: Hepatitis C
Intervention: Drug: rimantadine
Sponsors: The Leeds Teaching Hospitals NHS Trust; The Leeds Teaching Hospitals NHS Trust; Cancer Research UK
Recruiting - verified October 2012
Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Conditions: Liver Diseases, Alcoholic; Alcoholism; HIV; Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC); Other: Treatment as Usual
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Department of Veterans Affairs
Recruiting - verified January 2013
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection

Conditions: Cancer; Liver Cancer; Hepatocellular Carcinoma
Interventions: Drug: PI-88; Other: Placebo
Sponsors: Medigen Biotechnology Corporation; Medigen Biotechnology Corporation
Recruiting - verified June 2012
Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study

Condition: Chronic Hepatitis B
Intervention:
Sponsors: Foundation for Liver Research; Foundation for Liver Research
Recruiting - verified January 2013
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063 AM2)

Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (BOC); Drug: Placebo to boceprevir; Drug: Peginterferon alfa-2b (PEG); Drug: Ribavirin (RBV); Drug: Cross-Over Boceprevir Treatment
Sponsors: Merck; Merck
Recruiting - verified March 2013
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172 (MK-5172-013 AM3)

Condition: Hepatitis C
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Recruiting - verified March 2013
A Rapid 10-minute Liver MRI

Conditions: Underlying Liver Disease; Hepatitis; Fibrosis of Liver; Cirrhosis With Suspicion of Liver Cancer; Lesion on a Prior Ultrasound, CT or Outside MRI
Intervention:
Sponsors: University of Nebraska; University of Nebraska; Philips Medical Systems; Bracco Diagnostics, Inc
Recruiting - verified July 2012
Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment

Conditions: Hepatitis; Tuberculosis, Pulmonary
Intervention: Drug: isoniazid, rifampin, pyrazinamide
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified November 2012
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Condition: Chronic Hepatitis
Interventions: Drug: oral antiviral for HBV; Drug: tenofovir disoproxil fumarate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2013
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Condition: Chronic Hepatitis C
Intervention: Drug: statin
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Recruiting - verified August 2012
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients

Condition: Chronic Hepatitis B
Interventions: Drug: Peginterferon alfa-2a; Drug: Nucleos(t)ide analogue
Sponsors: Foundation for Liver Research; Foundation for Liver Research; Hoffmann-La Roche
Recruiting - verified January 2013
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure

Condition: Acute on Chronic Hepatic Failure
Interventions: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO); Drug: Placebo
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Recruiting - verified July 2012
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Condition: Hepatitis C, Chronic
Interventions: Drug: Pegylated interferon alfa 2b; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute; Merck
Recruiting - verified January 2013
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for High Risk Acute Variceal Bleeding in Cirrhotic Patients

Conditions: Decompensated Cirrhosis; Bleeding Varices
Interventions: Procedure: Transjugular intrahepatic portosystemic shunt; Drug: Non-selective beta blocker + Endoscopic treatment
Sponsors: Fourth Military Medical University; Fourth Military Medical University
Recruiting - verified February 2013
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)

Condition: Hepatitis C, Chronic
Interventions: Drug: MK-5172; Drug: Boceprevir; Drug: Placebo for MK-5172; Drug: Placebo for Boceprevir; Drug: Peg-interferon alfa-2b; Drug: Ribavirin
Sponsors: Merck; Merck
Recruiting - verified May 2013
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

Conditions: Hepatitis; HIV; Liver Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC); Washington D.C. Veterans Affairs Medical Center
Recruiting - verified January 2013
Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection

Conditions: Hepatitis B, Chronic; Liver Fibrosis
Intervention: Drug: Treatment with entecavir(Baraclude®)
Sponsors: RWTH Aachen University; RWTH Aachen University; Hannover Medical School; Hannover Clinical Trial Center GmbH
Recruiting - verified May 2013
Treatment of Recently Acquired Hepatitis C Virus Infection

Condition: Acute Hepatitis C
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute
Recruiting - verified November 2012
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

Condition: Chronic Hepatitis B
Intervention: Drug: Stopping TDF therapy
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2013
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Condition: Hepatitis C
Interventions: Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: BMS-790052 (NS5A Inhibitor); Drug: Ribavirin (RBV); Drug: BMS-650032 (NS3 Protease Inhibitor); Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a); Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: Ribavirin (RBV); Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: Ribavirin (RBV); Drug: BMS-790052 (NS5A Inhibitor); Drug: BMS-650032 (NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor); Drug: Placebo for Ribavirin (RBV); Drug: Placebo for Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
Observational Study of Persons With Hepatitis B Virus Infection in North America

Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2012
Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Condition: Hepatitis B
Interventions: Drug: Entecavir; Drug: Entecavir, Adefovir; Drug: Entecavir, Adefovir
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd
Recruiting - verified October 2012
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013
Study of a New MVA Vaccine for Hepatitis C Virus

Condition: Hepatitis C Infection
Interventions: Biological: MVA-NSmut; Biological: AdCh3NSmut; Biological: AdCh3NSmut1
Sponsors: Okairos; Okairos; University of Oxford; Oxford University Hospitals NHS Trust; University Hospital Birmingham
Recruiting - verified May 2013
Long-Acting Reversible Contraception

Condition: Contraception
Intervention: Drug: Contraception
Sponsors: FHI 360; FHI 360; National Institutes of Health (NIH)
Recruiting - verified March 2013
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Conditions: HIV Infection; Hepatitis C
Interventions: Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2013
The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test

Condition: Hepatitis B Virus Infection, Pregnancy
Intervention: Drug: antiviral therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified April 2013
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Conditions: Patients Undergoing Routine Health Care; Heart Diseases; Inflammatory Bowel Diseases; Autoimmune Disease; Inflammatory Disease; Blood Coagulation Disorders; Hepatitis C; Non-Metastatic Neoplasm
Intervention:
Sponsors: University of Chicago; University of Chicago
Recruiting - verified October 2012
Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers

Condition: Chronic Hepatitis C
Intervention:
Sponsors: Avera McKennan Hospital & University Health Center; Avera McKennan Hospital & University Health Center
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

Condition: HBeAg(+) Chronic Hepatitis B
Interventions: Drug: Clevudine; Drug: Clevudine + Peg-interferon
Sponsors: Bukwang Pharmaceutical; Bukwang Pharmaceutical
Recruiting - verified July 2012
Hepatitis B Research Network Pediatric Cohort Study (HBRN)

Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2013
Hepatitis B Research Network Adult Cohort Study

Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Condition: Chronic Hepatitis C Infection
Interventions: Drug: PSI-7977; Drug: Ribavirin; Drug: Pegylated-Interferon; Drug: GS-5885; Drug: GS-9669; Drug: Sofosbuvir/GS-5885 400/90 mg
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2012
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis

Condition: Alcoholic Hepatitis
Intervention:
Sponsors: University of Aarhus; University of Aarhus
Recruiting - verified October 2012
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Conditions: HIV; Hepatitis C; Liver Fibrosis
Interventions: Drug: Raltegravir; Drug: Ritonavir-boosted protease inhibitor
Sponsors: McGill University Health Center; McGill University Health Center; Merck; CIHR Canadian HIV Trials Network
Recruiting - verified August 2012
Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1

Condition: Hepatitis C
Interventions: Drug: Ribavirin "loading" dose given; Drug: "Priming" dose of ribavirin given; Drug: Group C ("Standard-of-Care")
Sponsors: Göteborg University; Göteborg University; The Swedish Research Council; Roche Pharma AG
Recruiting - verified February 2013
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Conditions: Chronic HIV Infection; HCV Coinfection
Intervention: Drug: Fosamprenavir
Sponsors: Fundacion SEIMC-GESIDA; Fundacion SEIMC-GESIDA; ViiV Healthcare
Recruiting - verified June 2011
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Condition: Liver Fibrosis Due to Chronic Hepatitis B Infection
Interventions: Drug: FG-3019; Drug: Placebo
Sponsors: FibroGen; FibroGen
Recruiting - verified January 2013
Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP

Condition: Lymphoma
Intervention: Drug: nucleoside analog reverse transcriptase inhibitor
Sponsors: Fudan University; Fudan University
Recruiting - verified February 2013
The Effect of Human Immunodeficiency Virus (HIV) Tat Protein on Hepatitis C Virus (HCV) Replication in an In-vitro Model System

Conditions: Human Immunodeficiency Virus (HIV); Hepatitis C, Chronic
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified September 2010
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Condition: Hepatitis B Virus
Interventions: Drug: pegIFN; Drug: pegIFNα-2a; Drug: PegIFN lambda; Drug: Entecavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012
Duration of Long-term Immunity After Hepatitis B Virus Immunization

Condition: Hepatitis B
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2013
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Conditions: Hepatitis C Infection; Thrombocytopenia
Interventions: Biological: romiplostim; Drug: ribavirin; Other: placebo; Biological: PEG-interferon alfa-2a; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified November 2012
Safety of Raltegravir When Given as Part of HIV Therapy in HIV/HCV Coinfected Individuals

Condition: HIV/ Hepatitis C Co-Infection
Interventions: Drug: Raltegravir (Isentress); Drug: Efavirenz (Sustiva)
Sponsors: University of Hawaii; University of Hawaii; University of Oxford
Not yet recruiting - verified June 2012
Hepatitis C Translating Initiatives for Depression Into Effective Solutions

Conditions: Hepatitis C; Depression
Intervention: Other: Depression collaborative care model
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2013
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin; Drug: Placebo
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified February 2013
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients

Conditions: Hepatitis B; Liver Transplantation
Intervention: Drug: Hepatitis B immune globulin
Sponsors: Grifols Biologicals Inc.; Instituto Grifols, S.A.
Recruiting - verified March 2013
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

Condition: Hepatitis C Virus Infection
Intervention:
Sponsors: Charles University, Czech Republic; Charles University, Czech Republic; Central Military Hospital, Prague, Czech Republic; General University Hospital, Prague; Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Recruiting - verified February 2013
Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Condition: Chronic Hepatitis C - Genotype 3
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified August 2012
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

Condition: Hepatitis C Virus
Intervention: Drug: ribavirin
Sponsors: University of Colorado, Denver; University of Colorado, Denver; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2012
Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV

Conditions: HIV; Hepatitis B
Interventions: Drug: Tenofovir/lamivudine/lopinavir-ritonavir; Drug: Zidovudine/lamivudine/lopinavir-ritonavir
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; National Center for AIDS/STD Control and Prevention, China CDC
Recruiting - verified June 2012
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection

Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Improvement of Humoral Immune Response With Hemodialysis on BK-F Membrane: Correlation to Soluble CD40 Clearing

Conditions: Chronic Renal Failure; Humoral Immune Alterations
Interventions: Procedure: High flux polymethylmetacrylate membrane; Procedure: Polysulfone membrane; Biological: Hepatitis B serological control; Biological: Seric sCD40 level
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified May 2013
Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

Conditions: Liver Transplantation; Hepatitis B; Liver Disease
Intervention: Drug: Entecavir
Sponsors: HepNet Study House, German Liverfoundation; HepNet Study House, German Liverfoundation; Hannover Medical School
Recruiting - verified December 2012
Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure

Condition: Hepatitis C
Intervention:
Sponsors: Fundacion IMIM; Fundacion IMIM
Recruiting - verified November 2012
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: COPEGUS
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Field Trial of Maternal Influenza Immunization in Asia

Condition: Influenza Human
Interventions: Biological: influenza vaccine; Biological: saline placebo
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; Bill and Melinda Gates Foundation; Seattle Children's Hospital; Tribhuvan University, Nepal; Johns Hopkins Bloomberg School of Public Health; Thrasher Research Fund
Recruiting - verified April 2013
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

Conditions: Chronic Hepatitis C; Oxidative Stress
Interventions: Drug: silymarin; Dietary Supplement: green tea extract (EGCG)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health (NIH)
Recruiting - verified October 2012
Baclofen to Reduce Alcohol Use in Veterans With HCV

Conditions: Hepatitis C; Alcohol Use Disorders
Interventions: Drug: baclofen; Drug: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2013
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

Condition: Hepatitis C
Interventions: Drug: Midazolam; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
Japanese Bridging Study Conducted in the United States

Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

Conditions: Hepatitis B; Hepatitis C; HIV; HIV Infections
Interventions: Behavioral: NCMIT; Behavioral: SCMIT
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2013
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon alfa-2a; Drug: Placebo and peginterferon
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified December 2012
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon (Pegasys) (52 weeks); Drug: Peginterferon (Pegasys) (96 weeks); Drug: Peginterferon (Pegasys) (48 weeks)
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified December 2012
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

Conditions: Carcinoma, Hepatocellular; Liver Cirrhosis, Alcoholic; Hepatitis, Alcoholic; Hepatitis, Chronic; Hepatitis, Viral, Human
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2012
Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

Condition: Hepatitis B
Intervention:
Sponsors: Kyoto University; Kyoto University
Recruiting - verified September 2012
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

Condition: Rift Valley Fever
Intervention: Biological: Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified August 2012
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma

Conditions: Liver Cancer; Hepatitis B; Hepatitis C; Hepatobiliary Cancers Liver; Hepatobiliary Cancers
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2012
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

Conditions: HIV; Hepatitis C; Infections
Intervention: Drug: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Institute of Mental Health (NIMH)
Recruiting - verified July 2009
NAT2 in Re-challenge of INH in Patients With Hepatitis

Conditions: Tuberculosis; Hepatotoxicity
Intervention: Drug: Isoniazid (Rifinah)
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; Department of Health, Executive Yuan, R.O.C. (Taiwan)
Recruiting - verified November 2012
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsors: Cangene Corporation; Cangene Corporation
Recruiting - verified July 2012
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Interventions: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2012
Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection

Condition: Dengue Fever
Intervention: Genetic: CLEC5A
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Centers for Disease Control and Prevention
Recruiting - verified September 2012
Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin

Conditions: Chronic Hepatitis C; Chronic Hepatitis B; Biopsy; Hemodialysis
Interventions: Procedure: Percutaneous liver biopsy; Procedure: Percutaneous liver biopsy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified December 2012
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C

Condition: Hepatitis C
Intervention:
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified June 2012
HIV-HCV Coinfection: Impact of Immune Dysfunction

Conditions: HIV Infections; Hepatitis
Intervention:
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified June 2012
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

Condition: Chronic Hepatitis C
Interventions: Drug: Pegylated interferon alfa-2a + ribavirin; Drug: Pegylated interferon alfa-2a + ribavirin; Drug: Pegylated interferon alfa-2a + ribavirin; Drug: Pegylated interferon alfa-2a + ribavirin; Drug: Pegylated interferon alfa-2a + ribavirin
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan; Department of Health, Executive Yuan, R.O.C. (Taiwan)
Recruiting - verified March 2013
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2012
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis Patients With Chronic Hepatitis C

Condition: Chronic Hepatitis C
Interventions: Drug: Pegylated interferon alfa-2a and ribavirin; Drug: Pegylated interferon alfa-2a
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan; Department of Health, Executive Yuan, R.O.C. (Taiwan)
Recruiting - verified February 2013
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2013
Characterization of Clonal B Cell Populations in HCV Infection

Condition: Hepatitis C
Intervention:
Sponsors: Rockefeller University; Rockefeller University; New York Presbyterian Hospital
Recruiting - verified December 2012
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.

Conditions: HIV Infections; Hepatitis B Virus
Intervention:
Sponsors: INC Research; INC Research; Abbott; Apotex Inc.; Aurobindo; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Cipla Ltd.; Gilead Sciences; HEC Pharm; Hetero USA; IPCA Laboratories Ltd.; Janssen R&D Ireland; Merck; Mylan Laboratories; Novartis; Pfizer; Prinston; Ranbaxy Inc.; Roche Pharma AG; Sciegen Pharmaceuticals; Strides Arcolab Ltd.; Teva Pharmaceuticals USA; ViiV Healthcare (represented by GlaxoSmithKline)
Recruiting - verified April 2013
Evaluation of Patients With Liver Disease

Conditions: Biliary Liver Cirrhosis,; Hemochromatosis; Hepatitis; Hepatolenticular Degeneration; Liver Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2012
Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

Condition: Liver Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2012
Hepatitis C Virus and the Humoral Immune System

Condition: Hepatitis C Virus
Intervention:
Sponsors: Rockefeller University; Rockefeller University; National Institute of Allergy and Infectious Diseases (NIAID); New York Presbyterian Hospital
Recruiting - verified December 2012
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation

Conditions: Liver Transplantation; Hepatitis B
Intervention: Biological: HBV vaccine booster
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified December 2012
Ribavirin Pregnancy Registry

Conditions: Birth Defects; Pregnancy Complications; Hepatitis C
Intervention:
Sponsors: INC Research; INC Research; Aurobindo; Genentech; Sandoz Inc.; Merck; Teva Pharmaceuticals USA; Kadmon Pharmaceuticals, LLC; Zydus Pharmaceuticals USA, Inc.
Recruiting - verified April 2013
Leukapheresis for Research on HCV-Coinfected Patients

Conditions: Hepatitis C; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2013
Study of Transfusion-Transmitted Infections

Condition: Virus Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified May 2013
Immune Response to Hepatitis C Virus

Condition: Hepatitis C
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2012
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

Condition: Hepatitis C
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2013

Find Clinical Trials in Arkansas for Hepatitis

Paid Clinical Trials

Get the PCT Newsletter!

Get timely and important notifications about new clinical trials in your area and up to the minute clinical trial news.
Email
	I'm Human!